Hong Kong Market Movement | TYK MEDICINES-B (02410) Rises Over 4% in Afternoon Session; Mesylate Aidotinib Tablets (TY-9591 Tablets) Proposed for Priority Review

Stock News01-09

TYK MEDICINES-B (02410) gained over 4% in afternoon trading. As of the time of writing, the stock was up 3.87%, trading at HK$14.21, with a turnover of HK$59.4029 million. The movement follows the company's announcement that its self-developed Class 1 new drug, Mesylate Aidotinib Tablets (TY-9591 Tablets), has been proposed by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for inclusion in the priority review list. The intended indication is for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) exon 19 deletion (19DEL) or exon 21 (L858R) substitution mutations, accompanied by central nervous system (CNS) metastases.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1132393260?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-09 14:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1132393260","market":"hk","top_or_hot":-1,"title":"Hong Kong Market Movement | TYK MEDICINES-B (02410) Rises Over 4% in Afternoon Session; Mesylate Aidotinib Tablets (TY-9591 Tablets) Proposed for Priority Review","media":"Stock News","content":"<p>TYK MEDICINES-B (02410) gained over 4% in afternoon trading. As of the time of writing, the stock was up 3.87%, trading at HK$14.21, with a turnover of HK$59.4029 million. The movement follows the company's announcement that its self-developed Class 1 new drug, Mesylate Aidotinib Tablets (TY-9591 Tablets), has been proposed by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for inclusion in the priority review list. The intended indication is for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) exon 19 deletion (19DEL) or exon 21 (L858R) substitution mutations, accompanied by central nervous system (CNS) metastases.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Market Movement | TYK MEDICINES-B (02410) Rises Over 4% in Afternoon Session; Mesylate Aidotinib Tablets (TY-9591 Tablets) Proposed for Priority Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Market Movement | TYK MEDICINES-B (02410) Rises Over 4% in Afternoon Session; Mesylate Aidotinib Tablets (TY-9591 Tablets) Proposed for Priority Review\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-09 14:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TYK MEDICINES-B (02410) gained over 4% in afternoon trading. As of the time of writing, the stock was up 3.87%, trading at HK$14.21, with a turnover of HK$59.4029 million. The movement follows the company's announcement that its self-developed Class 1 new drug, Mesylate Aidotinib Tablets (TY-9591 Tablets), has been proposed by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for inclusion in the priority review list. The intended indication is for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) exon 19 deletion (19DEL) or exon 21 (L858R) substitution mutations, accompanied by central nervous system (CNS) metastases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02410","symbol_name":"同源康医药-B","start_time":0,"source_url":"","article_id":"1132393260","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1132393260","pubTimestamp":1767939569,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"TYK MEDICINES-B (02410) gained over 4% in afternoon trading. As of the time of writing, the stock was up 3.87%, trading at HK$14.21, with a turnover of HK$59.4029 million. The movement follows the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","02410":"同源康医药-B","BK1161":"生物科技","TY":"Tri-Continental Corp","BK1515":"抗疫概念","09939":"开拓药业-B","BK1574":"生物医药B类股"},"translate_title":"港市动向|泰克医药-B(02410)午后涨超4%；甲磺酸艾多替尼片（TY-9591片）拟优先审评","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"09939":1,"02410":1,"TY":1},"content_text":"TYK MEDICINES-B (02410) gained over 4% in afternoon trading. As of the time of writing, the stock was up 3.87%, trading at HK$14.21, with a turnover of HK$59.4029 million. The movement follows the company's announcement that its self-developed Class 1 new drug, Mesylate Aidotinib Tablets (TY-9591 Tablets), has been proposed by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for inclusion in the priority review list. The intended indication is for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) exon 19 deletion (19DEL) or exon 21 (L858R) substitution mutations, accompanied by central nervous system (CNS) metastases.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1132393260","isCrawlerRequest":true}